BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 8019557)

  • 1. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intragenic homozygous deletion of the WT1 gene in Wilms' tumor.
    Tadokoro K; Fujii H; Ohshima A; Kakizawa Y; Shimizu K; Sakai A; Sumiyoshi K; Inoue T; Hayashi Y; Yamada M
    Oncogene; 1992 Jun; 7(6):1215-21. PubMed ID: 1350671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
    Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
    Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
    Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
    Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
    Haber DA; Buckler AJ
    New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of p53 in Wilms' tumors.
    Takeuchi S; Bartram CR; Ludwig R; Royer-Pokora B; Schneider S; Imamura J; Koeffler HP
    Mod Pathol; 1995 Jun; 8(5):483-7. PubMed ID: 7675765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
    Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
    Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
    Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
    Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel WT1 gene mutation associated with wilms' tumor and congenital male genitourinary malformation.
    Sakamoto J; Takata A; Fukuzawa R; Kikuchi H; Sugiyama M; Kanamori Y; Hashizume K; Hata JI
    Pediatr Res; 2001 Sep; 50(3):337-44. PubMed ID: 11518820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
    Grubb GR; Yun K; Reeve AE; Eccles MR
    Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
    Pritchard-Jones K; Fleming S
    Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
    Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
    Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
    Roberts DJ; Haber D; Sklar J; Crum CP
    Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene.
    Telerman A; Dodemont H; Degraef C; Galand P; Bauwens S; Van Oostveldt P; Amson RB
    Oncogene; 1992 Dec; 7(12):2545-8. PubMed ID: 1334252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biology of Wilms' tumor.
    Koo HP; Hensle TW
    Urol Clin North Am; 1993 May; 20(2):323-31. PubMed ID: 8388135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
    Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
    Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.